Literature DB >> 17570074

Complete deletion of ornithine transcarbamylase gene confirmed by CGH array of X chromosome.

J A Arranz1, I Madrigal, E Riudor, Ll Armengol, M Milà.   

Abstract

Ornithine transcarbamylase deficiency is an X-linked semidominant trait that is the most frequent inborn error of the urea cycle. Three hundred and fifty different mutations, including mostly point mutations and a small proportion of large rearrangements have been reported. Conventional molecular diagnosis is highly reliable for point mutations but can miss gross rearrangements. We describe a contiguous gene syndrome involving the RPGR, OTC and TM4SF2 genes in a male patient with severe neonatal OTC deficiency identified by the conventional molecular approach. Molecular characterization was ascertained by X chromosome CGH array and confirmed by MLPA. Complete deletion of the OTC gene led to absent OTC enzymatic activity in liver and to a severe clinical phenotype. The maternal phenotype, characterized by less severe hyperammonaemic crises associated with neurological impairment would result from a deficient but not null OTC activity due to random X chromosome inactivation in the liver. Our cases are similar toothers described presenting with OTC deficient phenotype in which OTC and contiguous genes are affected. Clinical expression would be conditioned by complete OTC deficiency in males and by X chromosome inactivation in females, leading to compensation by the normal allele in tissues such as blood or muscle but not sufficiently in liver. The application of high-resolution genetic techniques allows the characterization of causative mutations such as large deletions in order to guide genetic counselling and prenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17570074     DOI: 10.1007/s10545-007-0578-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  5 in total

1.  Large contiguous gene deletions in Sjögren-Larsson syndrome.

Authors:  Holly Engelstad; Gael Carney; Dana S'aulis; Janae Rise; Warren G Sanger; M Katharine Rudd; Gabriele Richard; Christopher W Carr; Omar A Abdul-Rahman; William B Rizzo
Journal:  Mol Genet Metab       Date:  2011-05-30       Impact factor: 4.797

2.  Clinical outcomes and the mutation spectrum of the OTC gene in patients with ornithine transcarbamylase deficiency.

Authors:  Jin-Ho Choi; Beom Hee Lee; Ja Hye Kim; Gu-Hwan Kim; Yoo-Mi Kim; Jahyang Cho; Chong-Kun Cheon; Jung Min Ko; Jung Hyun Lee; Han-Wook Yoo
Journal:  J Hum Genet       Date:  2015-09       Impact factor: 3.172

Review 3.  Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.

Authors:  Ljubica Caldovic; Iman Abdikarim; Sahas Narain; Mendel Tuchman; Hiroki Morizono
Journal:  J Genet Genomics       Date:  2015-05-19       Impact factor: 4.275

4.  Contiguous Xp11.4 Gene Deletion Leading to Ornithine Transcarbamylase Deficiency Detected by High-density Single-nucleotide Array.

Authors:  Mizuho Ono; Junnosuke Tsuda; Yoko Mouri; Junichi Arai; Tadao Arinami; Emiko Noguchi
Journal:  Clin Pediatr Endocrinol       Date:  2010-05-22

5.  X-chromosome tiling path array detection of copy number variants in patients with chromosome X-linked mental retardation.

Authors:  I Madrigal; L Rodríguez-Revenga; L Armengol; E González; B Rodriguez; C Badenas; A Sánchez; F Martínez; M Guitart; I Fernández; J A Arranz; Mi Tejada; L A Pérez-Jurado; X Estivill; M Milà
Journal:  BMC Genomics       Date:  2007-11-29       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.